EMERYVILLE, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that it will report its financial results for the third quarter ended September 30, 2018, after the market close, and will host a corporate update conference call and webcast on Thursday, November 8, 2018, at 4:30 PM Eastern Time.
|Conference Call Details|
|Thursday, November 8th @ 4:30 PM Eastern Time/1:30 PM Pacific Time|
|Replays available through November 22nd:|
Zogenix (ZGNX) is focused on developing therapies for patients with rare central nervous system (CNS) conditions that have limited or no treatment options, but face a critical need. For more information, visit www.zogenix.com.
Investors: Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987 | Andrew@lifesciadvisors.com
Media: David Polk
Senior Media Relations Strategist, Syneos Health
310-309-1029 | email@example.com